{"id":4744,"date":"2018-08-03T13:28:24","date_gmt":"2018-08-03T17:28:24","guid":{"rendered":"https:\/\/www.ncqa.org\/?page_id=4744"},"modified":"2020-02-14T09:36:57","modified_gmt":"2020-02-14T14:36:57","slug":"hedis-2017-final-ndc-lists","status":"publish","type":"page","link":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/","title":{"rendered":"HEDIS 2017 Final NDC Lists"},"content":{"rendered":"<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/HEDIS_2017_NDC_Lists_Final_4.zip\" target=\"_blank\" rel=\"noopener noreferrer\">HEDIS 2017 NDC List Technical Update<\/a><\/p>\n<h3>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/SAA-A_2017-final-1.xlsx\">Table SAA-A: Antipsychotic Medications<\/a><\/p>\n<h3>Annual Monitoring for Patients on Persistent Medications (MPM)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/MPM-B_2017-final-2.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table MPM-B: Drugs to Identify Members on Digoxin<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations:\u00a0<span class=\"TextRun SCXW44656498\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW44656498\">Table AMPM-B<\/span><\/span><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/MPM-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table MPM-C: Drugs to Identify Members on Diuretics\u00a0<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table AMPM-C.<\/li>\n<\/ul>\n<h3>Antibiotic Utilization (ABX)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/ABX-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table ABX-A: Antibiotic Medications<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/ABX-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table ABX-B: Antibiotic of Concern by NCQA Drug Class<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/ABX-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table ABX-C: All Other Antibiotics by NCQA Drug Class<\/a><\/p>\n<h3>Antidepressant Medications Management (AMM)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/AMM-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table AMM-C : Antidepressant Medications<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table AMM-C.<\/li>\n<\/ul>\n<h3>Appropriate Treatment for Children with Pharyngitis (CWP)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/CWP-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table CWP-C: Antibiotic Medications<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ACWP-C.<\/li>\n<\/ul>\n<h3>Asthma Medication Ratio (AMR)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/AMR-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table AMR-A: Asthma Controller and Reliever Medications<\/a><\/p>\n<h3>Avoidance of Antibiotic Treatment for Adults with Acute Bronchitis (AAB)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/AAB-D_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table AAB-D: Antibiotic Medications<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table AAAB-D.<\/li>\n<\/ul>\n<h3>Chlamydia Screening in Women (CHL)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/CHL-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table CHL-A: Prescriptions to Identify Contraceptives<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ACHL-A.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/CHL-E_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table CHL-E: Medication to Identify Exclusions<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ACHL-D.<\/li>\n<\/ul>\n<h3>Comprehensive Diabetes Care (CDC)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/CDC-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table CDC-A: Prescriptions to Identify Members with Diabetes<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ACDC-A.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/CDC-L_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table CDC-L: ACE Inhibitors\/ARBs.<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ACDC-M.<\/li>\n<\/ul>\n<h3>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/SSD-D_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table SSD-D: Antipsychotic Medications.<\/a><\/p>\n<h3>Disease Modifying Anti-Rheumatic Drug Therapy (ART)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/ART-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table ART-C: DMARDs<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table AART-D.<\/li>\n<\/ul>\n<h3>Follow-Up Care for Children Prescribed ADHD Medication (ADD)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/ADD-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table ADD-A: ADHD Medications<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table AADD-A.<\/li>\n<\/ul>\n<h3>Medication Management for People With Asthma (MMA)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/MMA-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table MMA-A: Asthma Medications<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/MMA-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table MMA-B: Asthma Controller Medications<\/a><\/p>\n<h3>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/APM-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table APM-A: Antipsychotic Medications<\/a><\/p>\n<h3>Non-Recommended PSA-Based Screening in Older Men (PSA)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/PSA-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table\u202fPSA-A: 5-ARIs<\/a><\/p>\n<h3>Osteoporosis Management in Women Who had a Fracture (OMW)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/OMW-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table OMW-C: Osteoporosis Therapies<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>\u202fAccountable Care Organizations: Table AOMW-D.<\/li>\n<\/ul>\n<h3>Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/PBH-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table PBH-B: Beta-Blocker Medications<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/PBH-D_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table PBH-D: Medications to Identify Exclusion (History of Asthma)<\/a><\/p>\n<h3>Pharmacotherapy Management of COPD Exacerbation (PCE)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/PCE-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table PCE-C: Systemic Corticosteroids<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/PCE-D_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table PCE-D: Bronchodilators<\/a><\/p>\n<h3>Potentially Harmful Drug-Disease Interactions in the Elderly (DDE)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DDE-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DDE-A: Potentially Harmful Drugs\u2014Rate 1<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADDE-C.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DDE-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DDE-B: Potentially Harmful Drugs\u2014Rate 1 and Rate 2<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADDE-D.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DDE-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DDE-C: Prescriptions to Identify Members With Dementia<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADDE-F.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DDE-D_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DDE-D: Potentially Harmful Drugs\u2014Rate 2<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADDE-G.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DDE-E_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DDE-E: Cox-2 Selective NSAIDs and Nonaspirin NSAIDs<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADDE-I.<\/li>\n<\/ul>\n<h3>Statin Therapy for Patients With Cardiovascular Disease (SPC)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/SPC-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table SPC-A: Medications to Identify Exclusions<\/a><\/p>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/SPC-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table SPC-B: High and Moderate-Intensity Statin Medications<\/a><\/p>\n<h3>Statin Therapy for Patients With Diabetes (SPD)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/SPD-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table SPD-A: High, Moderate and Low-Intensity Statin Prescriptions<\/a><\/p>\n<h3>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/APP-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table APP-A: Antipsychotic Medications<\/a><\/p>\n<h3>Use of Imaging Studies for Low Back Pain (LBP)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2020\/02\/20200214_LBP-A_2017.xlsx\">Table LBP-A: Corticosteroid Medications<\/a><\/p>\n<h3>Use of High-Risk Medications in the Elderly (DAE)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DAE-A_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DAE-A: High-Risk Medications<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADAE-A.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DAE-B_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DAE-B: High-Risk Medications with Days Supply Criteria<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADAE-B.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/DAE-C_2017-final.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table DAE-C: High-Risk Medications with Average Daily Dose Criteria<\/a><\/p>\n<p>Note: This table is also used for:<\/p>\n<ul>\n<li>Accountable Care Organizations: Table ADAE-C.<\/li>\n<\/ul>\n<h3>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)<\/h3>\n<p><a href=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2018\/08\/APC-A_2017-final-1.xlsx\" target=\"_blank\" rel=\"noopener noreferrer\">Table APC-A: Antipsychotic Medications<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>HEDIS<sup>\u00ae<\/sup> is a registered trademark of the National Committee for Quality Assurance (NCQA).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HEDIS 2017 NDC List Technical Update Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) Table SAA-A: Antipsychotic Medications Annual Monitoring for Patients on Persistent Medications (MPM) Table MPM-B: Drugs to Identify Members on Digoxin Note: This table is also used for: Accountable Care Organizations:\u00a0Table AMPM-B Table MPM-C: Drugs to Identify Members on Diuretics\u00a0 Note: [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":4742,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-4744","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HEDIS 2017 Final NDC Lists - NCQA<\/title>\n<meta name=\"description\" content=\"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HEDIS 2017 Final NDC Lists - NCQA\" \/>\n<meta property=\"og:description\" content=\"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/\" \/>\n<meta property=\"og:site_name\" content=\"NCQA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NCQA.org\" \/>\n<meta property=\"article:modified_time\" content=\"2020-02-14T14:36:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@NCQA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/\",\"url\":\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/\",\"name\":\"HEDIS 2017 Final NDC Lists - NCQA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ncqa.org\/#website\"},\"datePublished\":\"2018-08-03T17:28:24+00:00\",\"dateModified\":\"2020-02-14T14:36:57+00:00\",\"description\":\"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ncqa.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HEDIS\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"HEDIS Measures and Technical Resources\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/measures\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"HEDIS 2017 National Drug Code (NDC) License\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"HEDIS 2017 Final NDC Lists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ncqa.org\/#website\",\"url\":\"https:\/\/www.ncqa.org\/\",\"name\":\"NCQA\",\"description\":\"Measuring quality. Improving health care.\",\"publisher\":{\"@id\":\"https:\/\/www.ncqa.org\/#organization\"},\"alternateName\":\"National Committee for Quality Assurance\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ncqa.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ncqa.org\/#organization\",\"name\":\"NCQA\",\"alternateName\":\"National Committee for Quality Assurance\",\"url\":\"https:\/\/www.ncqa.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"contentUrl\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"width\":876,\"height\":673,\"caption\":\"NCQA\"},\"image\":{\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/NCQA.org\",\"https:\/\/x.com\/NCQA\",\"https:\/\/www.instagram.com\/ncqa_dc\/\",\"https:\/\/www.youtube.com\/@NcqaOrg\",\"https:\/\/www.linkedin.com\/company\/ncqa\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HEDIS 2017 Final NDC Lists - NCQA","description":"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/","og_locale":"en_US","og_type":"article","og_title":"HEDIS 2017 Final NDC Lists - NCQA","og_description":"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.","og_url":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/","og_site_name":"NCQA","article_publisher":"https:\/\/www.facebook.com\/NCQA.org","article_modified_time":"2020-02-14T14:36:57+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@NCQA","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/","url":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/","name":"HEDIS 2017 Final NDC Lists - NCQA","isPartOf":{"@id":"https:\/\/www.ncqa.org\/#website"},"datePublished":"2018-08-03T17:28:24+00:00","dateModified":"2020-02-14T14:36:57+00:00","description":"The HEDIS National Drug Code (NDC) Lists are used for multiple products and includes medication lists referenced in the Volume 2 Technical Specifications for Health Plans and Physician Measurement.","breadcrumb":{"@id":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/hedis-2017-final-ndc-lists\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ncqa.org\/"},{"@type":"ListItem","position":2,"name":"HEDIS","item":"https:\/\/www.ncqa.org\/hedis\/"},{"@type":"ListItem","position":3,"name":"HEDIS Measures and Technical Resources","item":"https:\/\/www.ncqa.org\/hedis\/measures\/"},{"@type":"ListItem","position":4,"name":"HEDIS 2017 National Drug Code (NDC) License","item":"https:\/\/www.ncqa.org\/hedis\/measures\/hedis-2017-national-drug-code-ndc-license\/"},{"@type":"ListItem","position":5,"name":"HEDIS 2017 Final NDC Lists"}]},{"@type":"WebSite","@id":"https:\/\/www.ncqa.org\/#website","url":"https:\/\/www.ncqa.org\/","name":"NCQA","description":"Measuring quality. Improving health care.","publisher":{"@id":"https:\/\/www.ncqa.org\/#organization"},"alternateName":"National Committee for Quality Assurance","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ncqa.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ncqa.org\/#organization","name":"NCQA","alternateName":"National Committee for Quality Assurance","url":"https:\/\/www.ncqa.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","contentUrl":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","width":876,"height":673,"caption":"NCQA"},"image":{"@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/NCQA.org","https:\/\/x.com\/NCQA","https:\/\/www.instagram.com\/ncqa_dc\/","https:\/\/www.youtube.com\/@NcqaOrg","https:\/\/www.linkedin.com\/company\/ncqa\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/4744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/comments?post=4744"}],"version-history":[{"count":0,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/4744\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/4742"}],"wp:attachment":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/media?parent=4744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}